Esperion Therapeutics
ESPR
ESPR
187 hedge funds and large institutions have $1.91B invested in Esperion Therapeutics in 2018 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 69 increasing their positions, 54 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
7.25% more ownership
Funds ownership: 92.75% → 100% (+7.2%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
36% less call options, than puts
Call options by funds: $83.1M | Put options by funds: $130M
Holders
187
Holding in Top 10
7
Calls
$83.1M
Puts
$130M
Top Buyers
| 1 | +$40.1M | |
| 2 | +$34M | |
| 3 | +$27.6M | |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$22.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$20.6M |
Top Sellers
| 1 | -$20M | |
| 2 | -$18.3M | |
| 3 | -$18.3M | |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$15.1M |
| 5 |
Goldman Sachs
New York
|
-$10.3M |